FMP
Optimistic Outlook For Halozyme in 2022
Jan 19, 2022 7:59 PM - Davit Kirakosyan
Image credit: FMP
Halozyme Therapeutics, Inc. (NASDAQ:HALO) increased its revenue guidance for 2022, expecting total revenue to be in the range of $530-560 million, representing 23-26% growth year-over-year. The company’s primary revenue stream is from royalties, which are expected to increase approximately 244% from 2020 and 50% year-over-year to $300 million.
Analysts at Berenberg Bank expect strong growth in royalty revenues to be largely driven by DARZALEX and Phesgo for the near term until the next set of product launches debut in the 2023-25 timeframe, assuming a positive outcome from the Phase III studies, results of which are expected in 2022-23.
Other Blogs
Sep 11, 2023 1:38 PM - Rajnish Katharotiya
P/E Ratios Using Normalized Earnings
Price to Earnings is one of the key metrics use to value companies using multiples. The P/E ratio and other multiples are relative valuation metrics and they cannot be looked at in isolation. One of the problems with the P/E metric is the fact that if we are in the peak of a business cycle, earni...
Sep 11, 2023 1:49 PM - Rajnish Katharotiya
What is Price To Earnings Ratio and How to Calculate it using Python
Price-to-Earnings ratio is a relative valuation tool. It is used by investors to find great companies at low prices. In this post, we will build a Python script to calculate Price Earnings Ratio for comparable companies. Photo by Skitterphoto on Pexels Price Earnings Ratio and Comparable Compa...
Oct 17, 2023 3:09 PM - Davit Kirakosyan
VMware Stock Drops 12% as China May Hold Up the Broadcom Acquisition
Shares of VMware (NYSE:VMW) witnessed a sharp drop of 12% intra-day today due to rising concerns about China's review of the company's significant sale deal to Broadcom. Consequently, Broadcom's shares also saw a dip of around 4%. Even though there aren’t any apparent problems with the proposed solu...
